MedPath

Analyzes of Nasal Tissue-resident Memory Immune Cells and Peripheral Memory Cells Able to Migrate to Airway Tissues (MUCOVAC)

Not Applicable
Completed
Conditions
Healthy Volunteers
Registration Number
NCT06469359
Lead Sponsor
Centre Hospitalier Universitaire de Saint Etienne
Brief Summary

Clinical evaluation of vaccines against respiratory viruses is currently based on the analysis of systemic immune responses, whereas respiratory immunity is the first line of defense against respiratory pathogens. In addition to secretory immunoglobulin A (IgA) in mucosal fluids which are essential to neutralize the pathogens at mucosal surfaces, tissue-resident memory immune cells have been shown to be crucial in protection. Furthermore, memory immune cells in blood able to migrate to airway tissues also play a crucial role. Airway immune responses have not been studied a lot due to the lack of a standardized methodology to evaluate them in humans.

Detailed Description

The goal of this study is to develop a methodology to collect and analyze nasal tissue-resident memory T and B cells and to evaluate peripheral memory T and B cells expressing airway homing markers in healthy volunteers. Three devices for nasal cell sampling will be compared. Tissue-resident and peripheral memory immune responses will be determined using flow cytometry and correlated with humoral and cellular responses, as well as with gene expression at mucosal and systemic levels. .

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Affiliated to the Social Security System
  • Signed informed consent form
Exclusion Criteria
  • History of recurrent nosebleeds or systemic hemorrhages
  • Previous injury or surgery which modified nasal cavity (e.g. deviated nasal septum)
  • Individuals receiving anticoagulant therapy
  • Individuals who experienced a severe respiratory infection leading to hospitalization in the last 6 months
  • Individuals who received an antibiotic therapy for respiratory infection or any other infection in the last 6 months
  • Immunocompromised individuals, or individuals taking immunosuppressed therapy or having a pathology (chronic infection, auto-immune disease) which could impact on immunity based on investigator's opinion
  • Unstable chronic pathology
  • People deprived of liberty or hospitalized without any consent
  • People under guardianship (authorship or curators)
  • Individuals who received a vaccine (any vaccine) in the last 30 days
  • Pregnant or breast-feeding people
  • Individuals experiencing respiratory infection symptoms. Inclusion will be postponed up to 7 days after the symptom resolution

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
Frequency of resident memory lymphocytes in the nasal mucosa measured by FLOQSwabAt inclusion, one month, two months

This outcome is measured by the three devices :

* FLOQSwab

* Rhino-Pro Curette

* Cervical brush

Secondary Outcome Measures
NameTimeMethod
Visual analog scale for painAt inclusion, one month, two months

Scale from 0 to 10 (0 = no pain, 10 = intolerable pain)

This outcome is measured by the three devices :

* FLOQSwab

* Rhino-Pro Curette

* Cervical brush

Frequencies of resident memory T and B lymphocytesAt inclusion, one month, two months

Frequencies of resident memory T and B lymphocytes are measured by the three devices :

* FLOQSwab

* Rhino-Pro Curette

* Cervical brush

Expression levels of respiratory mucosal migration markers on peripheral memory lymphocytesAt inclusion, one month, two months

This outcome is measured by the three devices :

* FLOQSwab

* Rhino-Pro Curette

* Cervical brush

Trial Locations

Locations (1)

Centre Hospitalier Universitaire

🇫🇷

Saint-Étienne, France

Centre Hospitalier Universitaire
🇫🇷Saint-Étienne, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.